Catalyst
Slingshot members are tracking this event:
Results from Calithera Bio's (CALA) Phase I Study of CB-839 in Combination with Everolimus or Cabozantinib in Renal Cell Carcinoma Presented
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CALA |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 05, 2018
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Cb-839, Phase 1 Trial Results, Everolimus, Cabozantinib, Renal Cell Carcinoma
